Tempest Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Amount
Tempest Therapeutics, Inc. (TPST) reported Effective Income Tax Rate Reconciliation, Tax Credit, Amount of $1.14 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCredits · last filed 2025-03-27
- Tempest Therapeutics, Inc. effective income tax rate reconciliation, tax credit, amount for fiscal 2024 was $1.14M, a 35.89% increase from fiscal 2023.
- Tempest Therapeutics, Inc. effective income tax rate reconciliation, tax credit, amount for fiscal 2023 was $836.00K, a 28.73% decline from fiscal 2022.
- Tempest Therapeutics, Inc. effective income tax rate reconciliation, tax credit, amount for fiscal 2022 was $1.17M, a 52.93% increase from fiscal 2021.
- Tempest Therapeutics, Inc. effective income tax rate reconciliation, tax credit, amount for fiscal 2021 was $767.00K, a 26.99% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Amount 12 month |
|---|---|
| 2024-12-31 | $1.14M 10-K · filed 2025-03-27 |
| 2023-12-31 | $836.00K 10-K · filed 2025-03-27 |
| 2022-12-31 | $1.17M 10-K · filed 2024-03-19 |
| 2021-12-31 | $767.00K 10-K · filed 2023-03-22 |
| 2020-12-31 | $604.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |